<DOC>
	<DOCNO>NCT01354314</DOCNO>
	<brief_summary>The purpose study see paroxetine fluconazole safe effective treatment problem memory , concentration , think , judgment people infect HIV . Paroxetine antidepressant approve FDA treat major depression . Fluconazole antifungal medication approve FDA treat fungal infection .</brief_summary>
	<brief_title>Study Paroxetine Fluconazole Treatment HIV Associated Neurocognitive Disorder</brief_title>
	<detailed_description>The study 24 week double-blind , placebo-controlled 2x2 factorial design pilot Phase I/II study 60 HIV+ individual HAND . Participants randomly assign one four group : 1 ) fluconazole 100 mg every 12 hour orally per day , 2 ) paroxetine 20mg every evening orally per day , 3 ) fluconazole 100mg every 12 hour orally per day paroxetine 20mg every evening orally per day 4 ) placebo . Primary Aim : To obtain preliminary data evaluate efficacy fluconazole and/or paroxetine decrease CSF lipid protein marker oxidative stress [ CSF ceramide ( C18:0 level ) 3-nitrosylated protein ] . Secondary Aims : ) To evaluate safety tolerability fluconazole and/or paroxetine HIV+ individual HAND ii ) To evaluate effect fluconazole and/or paroxetine neurocognitive performance HIV+ individual HAND iii ) To evaluate effect fluconazole and/or paroxetine functional performance HIV+ individual HAND iv ) To evaluate CNS penetration fluconazole paroxetine 24 week treatment v ) To obtain preliminary data evaluate efficacy fluconazole and/or paroxetine improve abnormal image marker measure magnetic resonance spectroscopy ( MRS ) arterial spin labeling</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>HIV+ base ELISA confirm either Western blot plasma HIV RNA capable providing inform consent age range : 1865 year presence neuropsychological test impairment define performance least 1.0 standard deviation agematched educationmatched control three independent neuropsychological test screen visit , performance least 2.0 standard deviation agematched educationmatched control one independent neuropsychological test least 1.0 standard deviation agematched educationmatched control second independent neuropsychological test screen visit stable HAART regimen 3 month plan change antiretroviral regimen study period ( confirmed discussion patient 's primary provider ) follow lab value within 2 week prior entry : hemoglobin &gt; 8.9 g/dl , absolute neutrophil count &gt; 500 cells/mm3 , platelet count &gt; 50,000 cells/mm3 , ALT &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 3 X upper limit normal , serum creatinine &gt; = 2 X upper limit normal negative serum urine betaHCG pregnancy test woman reproductive potential ( reach menopause undergone hysterectomy , oophorectomy , tubal ligation ) neurological examination physician reveal contraindication lumbar puncture . If examination suggest possible spaceoccupying brain mass lesion , neuroimaging CT MRI must confirm absence mass lesion . current past opportunistic CNS infection ( fungal nonfungal ) study entry current systemic fungal infection current past use fluconazole within 30 day screen visit history current clinical evidence schizophrenia history chronic neurological disorder multiple sclerosis uncontrolled epilepsy active symptomatic AIDS defining opportunistic infection within 30 day prior study entry history abnormal medical illness current severe affective disorder ( e.g. , depression suicidal intention ) opinion investigator would constitute safety risk patient interfere ability patient complete study treatment anticoagulant include coumadin , heparin , low molecular weight heparin would contraindication lumbar puncture HIV+ individual moderate severe confounding illness prior use SSRI 's within 1 month screen active substance abuse ( illicit drug and/or control medication ) active severe alcohol abuse , evidence history intake urine toxicology visit prior study entry ( start study medication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Neurocognitive impairment</keyword>
	<keyword>Memory</keyword>
	<keyword>Dementia</keyword>
	<keyword>CSF marker</keyword>
	<keyword>Functional assessment</keyword>
	<keyword>MRS</keyword>
	<keyword>Magnetic resonance spectroscopy</keyword>
	<keyword>Arterial spin labeling</keyword>
	<keyword>SSRI</keyword>
</DOC>